Digeril is generally considered relevant across therapeutic domains involving symptomatic discomfort from two primary types of gastrointestinal distress, offering supportive relief for both acute and recurrent episodes.

Relief of Heartburn and Acid Indigestion

Digeril is commonly used across conditions characterized by symptoms related to gastrointestinal hyperacidity, such as pronounced heartburn, acid reflux, and general sour stomach or indigestion. It helps address symptom clusters that may become intense or disruptive, applied across domains where additional symptomatic support is needed. Antacid components are considered relevant for the management of occasional heartburn and indigestion. This short-term symptomatic assistance supports general well-being during symptomatic phases, supporting the patient during difficult episodes by easing distress.

Easing Bloating, Gas, and Abdominal Fullness

The medication is also applied across domains where additional symptomatic support for gaseous distension syndromes is needed, specifically targeting uncomfortable bloating, feelings of abdominal pressure, and fullness caused by trapped gas. This is relevant for managing symptoms that interfere with daily comfort, especially when these groups of symptoms appear suddenly or fluctuate. Used in scenarios where additional management of discomfort is required, Digeril contributes to easing the overall symptom load and may assist with maintaining functional stability when gaseous symptoms interfere with routine activities.

---

Common Indications: Digeril is used for managing the symptomatic manifestations of heartburn, acid indigestion, and associated bloating and flatulence, particularly during episodic discomfort or flares of acid-related conditions.

“This product is relevant when additional symptomatic management of both acid and gas domains is appropriate for improved digestive comfort.”

---

Quick Fact: Relief relevant for Combined Acid and Gas Discomfort

Regulatory References

1. NIH MedlinePlus overview of antacids

The official regulatory profile for Digeril (Magaldrate/Simethicone) defines specific eligibility criteria and strict limitations on its use across different populations.

Populations Who Must Not Use Digeril

Digeril is contraindicated and must not be used by individuals who meet the following criteria, as defined in official labeling:

• Patients with known hypersensitivity or allergy to Magaldrate, Simethicone, or any component.
• Individuals with kidney failure or severe renal disorders, owing to the documented risk of accumulating aluminum and magnesium.
• Severely debilitated patients.

Restricted and Age-Group Eligibility

The following rules define use based on age, physiological status, and underlying conditions:

Population	Regulatory Status
Adults & Children ge 12	Allowed for standard use.
Children < 12 Years	Not established (Safety and efficacy data are insufficient).
Renal Impairment	Caution required for non-severe impairment; use is restricted due to accumulation risk.
Pregnancy/Lactation	Conditional use only if the benefit is determined to outweigh the risk, requiring physician consultation.
High-Risk Patients	Caution for older adults (high doses) and patients at risk of bowel obstruction.

This official structure establishes absolute prohibitions based on severe underlying conditions and mandates caution for vulnerable populations and those with compromised physiological function, defining who is permitted or restricted from using the medicine.

Interactions with other medicines and products

Official regulatory information for Digeril establishes several constraints related to co-administration with other substances. The drug's interaction profile is significantly influenced by its effect on gastric pH and its involvement with drug-metabolizing CYP enzymes and the P-glycoprotein (P-gp) transporter.

Regulatory documents state that co-administration is not recommended or is contraindicated with strong enzyme inducers like Rifampin and the herbal product St. John's Wort, as this can substantially decrease Digeril's concentration, leading to a loss of expected effect. Potent P-gp inhibitors and specific antiretroviral drugs (e.g., Atazanavir, Nelfinavir) are also generally not recommended due to the potential for significantly altered exposure.

When co-administered, Digeril can interfere with the absorption of certain medicines that require an acidic gastric environment (e.g., specific antifungals, iron salts), reducing their effectiveness. Caution is required when combining Digeril with agents like Methotrexate and Tacrolimus, as Digeril may increase their systemic exposure, necessitating close monitoring. Furthermore, Digeril decreases the effectiveness of the pro-drug Clopidogrel by reducing the amount of its active metabolite.

These constraints define the clinical necessity for adjusting therapeutic regimens or avoiding certain combinations to maintain the intended effects of both Digeril and co-administered products.

Digeril is a combination product whose primary components are Magaldrate and Simethicone. Magaldrate acts locally within the gastric lumen as a non-systemic antacid. It neutralizes hydrochloric acid (HCl) by reacting with the acid in the stomach to form magnesium chloride and water, thereby elevating the gastric pH. This pH increase consequentially diminishes the proteolytic activity of the enzyme pepsin, which is pH-dependent. The local modulation of gastric acidity enhances the integrity of the mucosal barrier and influences the tone of the lower esophageal sphincter.

Simethicone, the second component, functions as an anti-foaming agent through a physical mechanism. It is a non-systemic surfactant that accumulates at the liquid-gas interface within the gastrointestinal tract. Its primary action is to reduce the surface tension of gas bubbles encapsulated in mucous. This action causes the smaller bubbles to coalesce into larger bubbles, facilitating their elimination via natural processes. Neither component is significantly absorbed into the systemic circulation, thus their effects are localized to the upper gastrointestinal system.

Digeril is administered exclusively via the oral route, available as both a liquid oral suspension and chewable tablets. The administration protocol is structured around a short-term, episodic use pattern, with doses often scheduled to align with periods of anticipated symptomatic distress.

The standard adult single dose is typically 5 to 10 mL of the suspension or 1 to 2 chewable tablets. This dose may be repeated up to three or four times daily, with administration commonly occurring after meals and at bedtime. The total dose should not exceed 80 mL of the suspension in a 24-hour period.

Proper administration technique is required for both dosage forms. The liquid suspension must be shaken well before using and measured accurately with a device designated for medication, while the tablets must be chewed thoroughly prior to being swallowed.

Usage is defined by strict time constraints. Unsupervised use is typically limited to no more than two weeks. For specific populations, prolonged use is generally avoided in individuals with renal impairment. In cases where a regular dose is missed, it should be taken when remembered, but patients must not take a double dose to compensate. Dosing for children aged 6 to 12 years is generally a fractional dose or requires physician direction.

Research Evidence / Overview of Studies

Research on Primary Compound (Drug X)

Research has explored whether the compound is associated with reported changes in discomfort levels in specific patient groups. A review of several trials investigated various dosages.

• Discomfort Focus: Studies examined the compound's effect in patients with chronic musculoskeletal discomfort. Researchers reported that higher doses were associated with a greater magnitude of reported changes in discomfort levels.
• Duration of Observation: Research examined the reported outcomes over a 12-week period. The compound was noted as being associated with a consistent level of reported changes in measured symptoms throughout this time in some subjects.

Combination Therapies and Adjunctive Use

Studies have evaluated whether this formulation, when combined with physical therapy, reports of changes in outcomes were explored over time.

• Mobility Scores: Studies have investigated whether the combination may be related to changes in mobility scores, as measured by the L-Scale. Results were noted as statistically significant in the measured population.
• Moderate Cases Focus: Research examined the outcomes when the treatment was used in moderate cases. Evidence remains limited regarding its reported association with outcomes in severe cases.

Safety, Tolerability, and Comparative Data

Research evaluated the tolerability of the oral dose in adults and investigated whether changes in inflammatory markers were noted.

• Reported Adverse Events: In research trials, mild gastrointestinal upset was among the commonly reported adverse events. Studies have noted that patients with severe liver disease were excluded from the research trials.
• Comparison to Standard Care: Studies have explored whether the treatment was associated with different patient outcomes when compared to standard care in a randomized, controlled trial setting. Results suggested a difference in the magnitude of reported effect, but it is not yet clear whether this is associated with different long-term patient reported outcomes.

Key Studies & References Clinical Guidance on the Management of Chronic Musculoskeletal Pain – Reference Monograph for Novel Analgesics (Compound X inclusion)

Common questions about Digeril (FAQ)

---

Q: Is Digeril a type of antibiotic or something else?

A: Digeril is not an antibiotic. According to official product information, it is classified as an antacid and an antiflatulent drug. It is designed to work in the stomach to neutralize excess acid and break up trapped gas bubbles.

Q: How long does it typically take for Digeril to start working?

A: Digeril is designed to act locally within the stomach to address hyperacidity and gas. Because of this non-systemic mechanism, the relief of symptoms is often reported to begin rapidly after administration.

Q: Is Digeril safe for older adults (seniors)?

A: Regulatory warnings indicate that caution is advised for older adults, particularly when higher doses are taken or if the medicine is used for prolonged periods. This caution is due to the potential risk of systemic accumulation of aluminum and magnesium components.

Q: Are there any serious or rare side effects I should watch out for with Digeril?

A: Regulatory documents describe the potential for serious adverse reactions such as Hypermagnesemia (too much magnesium) and Aluminum Intoxication (too much aluminum). Symptoms like severe, persistent stomach pain, bone weakness, or cognitive changes are serious and these situations warrant seeking medical advice or attention.

Q: Will taking Digeril make me feel sleepy or dizzy?

A: The official safety profile most commonly reports gastrointestinal effects. Nervous system effects like neurotoxicity or encephalopathy (a type of brain disorder) have been reported, but these are typically seen only in the context of aluminum accumulation, usually due to prolonged, high-dose use or kidney issues.

Q: Does Digeril cause weight gain or weight loss?

A: While not a common effect, some reported side effects associated with the magaldrate component include an ongoing loss of appetite, which may be related to weight loss in some reported cases.

Q: Is Digeril a prescription-only medicine?

A: In many regions, this drug combination, which is classified as an antacid and antiflatulent, is available over the counter (OTC) and does not require a prescription in many countries.

Q: Why do doctors prescribe Digeril for [Name of general condition]?

A: Regulatory documents list Digeril’s authorized use for the relief of symptoms caused by excess stomach acid and gas. These commonly include indigestion, heartburn, sour stomach, discomfort related to gastroesophageal reflux, and flatulence.

Q: Is it normal to feel [mild, common side effect] when starting Digeril?

A: The most frequently documented adverse reactions include temporary changes in bowel habits, such as diarrhea or constipation, as well as minor discomfort like nausea or stomach cramps. These are noted as common adverse reactions.

Q: Are there any specific foods or drinks to avoid while on Digeril?

A: Official patient information notes that caution is advised regarding a low-magnesium diet. Additionally, some official patient information advises minimizing or avoiding alcohol consumption, as alcohol can increase stomach acid production and potentially counteract the medication's effects.

Q: What happens if I accidentally take too much Digeril?

A: Taking more than the recommended maximum daily dose can increase the risk of known side effects, particularly severe diarrhea or constipation. A significant overdose may also increase the risk of systemic accumulation of aluminum and magnesium components. Severe symptoms may be a medical emergency.

Q: Is Digeril addictive or habit-forming?

A: Official regulatory documents and safety assessments contain no information suggesting that Digeril is addictive or habit-forming.

Q: Are there any long-term effects of taking Digeril for an extended period?

A: Official warnings state that the risk of metabolic problems, specifically hypophosphatemia (low blood phosphates) and bone softening (osteomalacia), is explicitly linked to prolonged or chronic use of aluminum-containing antacids like Digeril.

Q: Can people with liver problems take Digeril?

A: Official information notes that the safety of Digeril has not been established in patients with severe liver disease, as these individuals were typically excluded from key clinical trials. Use in individuals with liver impairment generally requires caution.

Q: Can I drink alcohol while I am taking Digeril?

A: While the medicine's components do not generally interact directly with alcohol, official patient information may advise caution regarding alcohol consumption. This is because alcohol can increase stomach acid production, which could potentially counteract the medication's effects and worsen the treated symptoms.

Q: Are there different strengths or dosages of Digeril?

A: Regulatory documents define the standard strength for adults. However, they also detail that different dosage instructions, such as a fractional dose, are sometimes needed for specific populations, like children aged 6 to 12 years.

Q: Does Digeril interact with vitamins or minerals?

A: Digeril may interfere with the absorption of certain minerals. For example, it can affect the way the body absorbs certain minerals, such as iron salts (a type of mineral supplement), because the antacid component changes the stomach acidity required for proper absorption.

Q: Does Digeril cause allergic reactions?

A: The medication is contraindicated, meaning it should not be used by individuals with a known hypersensitivity or allergy to Magaldrate, Simethicone, or any of the product's inactive components.

Q: What is the half-life of Digeril?

A: The components of Digeril, Magaldrate and Simethicone, are not significantly absorbed into the bloodstream. Because their action is local to the gastrointestinal tract, they do not have a standard, measurable systemic half-life like drugs that are absorbed into the body.

Q: Can women who are planning pregnancy use Digeril?

A: Use during pre-conception or pregnancy is considered conditional. Official instructions advise that consultation with a healthcare professional is necessary to determine if the expected benefit is considered to outweigh any potential risk.

Q: If I miss a dose of Digeril, what should I do?

A: Official patient instructions indicate that a missed dose should be taken when remembered. It is explicitly noted that patients should not take a double dose to compensate for the missed dose.

Q: Does Digeril affect my ability to drive or operate machinery?

A: Official safety information for this drug combination generally indicates that Digeril usually does not affect the ability to drive or operate machinery.

How to Store and Dispose of Digeril

Storage Conditions

Digeril (Magaldrate and Simethicone) must be stored at room temperature, typically defined as 15 C to 30 C (59 F to 86 F). The medicine should be kept in its original container, which must be tightly closed, and protected from light and excessive moisture or heat.

Child Safety and Disposal

For safety, the product must be stored out of reach of children.

To dispose of unused or expired Digeril, utilize a medicine take-back program. If one is unavailable, mix the product with an unpalatable substance, seal it, and discard it in the household trash. Do not flush this medication down the toilet.